What is the company's updated financial outlook for 2018?

Elevance Health (Anthem) reaffirmed its 2018 net income guidance to be greater than $14.28 per share. Excluding approximately $0.72 per share in net negative adjustment items, the company expects adjusted net income to be greater than $15.00 per share.

What items are excluded from the 2018 financial guidance?

The guidance specifically excludes the impact of the acquisition completed on February 15, 2018, any investment gains or losses, other than temporary impairment losses, and additional amortization of other intangible assets beyond what was already included in prior outlooks.

When will the company discuss this guidance with investors?

Company officers are scheduled to discuss this guidance with investors during meetings occurring between March 13, 2018, and March 30, 2018.

Is this 8-K report providing new financial results for the quarter ending March 2018?

No, this 8-K filing is a Regulation FD disclosure. It primarily serves to reaffirm the company's financial guidance for the full year 2018 and inform investors about upcoming discussions, rather than reporting new quarterly financial results.

ELV 8-K: Regulation FD — Mar 13, 2018

Summary

Elevance Health, Inc. (formerly Anthem, Inc.) filed an 8-K on March 13, 2018, primarily to update investors on financial guidance and discuss recent business developments. The company reaffirmed its full-year 2018 net income guidance, projecting it to be greater than $14.28 per share. After accounting for approximately $0.72 per share in net negative adjustment items, the adjusted net income is expected to exceed $15.00 per share. This guidance notably excludes the impact of a recent acquisition completed on February 15, 2018, involving Freedom Health, Optimum HealthCare, and America’s 1st Choice of South Carolina, as well as other potential financial items like investment gains/losses and additional amortization. The filing also serves to inform investors about upcoming meetings where this guidance will be reiterated. While the 8-K does not contain new material financial results, it signals the company's confidence in its 2018 financial outlook and provides clarity on what is included and excluded from its projections. Investors should note the forward-looking nature of this information and consult the company's other SEC filings for a comprehensive understanding of associated risks and uncertainties.

Key Highlights

1Reaffirmed full-year 2018 net income guidance: greater than $14.28 per share.
2Projected adjusted net income for 2018 to be greater than $15.00 per share, excluding net negative adjustment items.
3Guidance excludes impact from the February 15, 2018 acquisition of Freedom Health, Optimum HealthCare, and America’s 1st Choice of South Carolina and related entities.
4Guidance also excludes investment gains or losses, other than temporary impairment losses, and additional amortization of other intangible assets.
5Company officers will discuss this guidance with investors between March 13, 2018, and March 30, 2018.
6The filing serves as a Regulation FD disclosure regarding financial outlook.
7Contains standard forward-looking statement disclaimers, highlighting various risks and uncertainties.

Elevance Health, Inc. 8-K Report, Regulation FD Disclosure (Mar 13, 2018)

Summary

Key Highlights

Frequently Asked Questions